This is the authors' abstract. We don't add key points for this paper.
Once-weekly efanesoctocog alfa provides high sustained factor VIII activity with superior bleeding prevention as compared with prestudy factor VIII prophylaxis in previously treated patients 12 years of age or older with severe hemophilia A. Data on outcomes of efanesoctocog alfa treatment in children younger than 12 years of age with severe hemophilia A are limited.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Malec et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: